-+ 0.00%
-+ 0.00%
-+ 0.00%

INmune Bio says XPro1595 hits white matter MRI biomarker endpoint in Phase 2 Alzheimer’s trial

PUBT·06/02/2026 12:07:56
Listen to the news
INmune Bio says XPro1595 hits white matter MRI biomarker endpoint in Phase 2 Alzheimer’s trial
  • INmune Bio reported new MRI biomarker results from its Phase 2 MINDFuL trial of XPro1595 in early Alzheimer’s disease.
  • The analysis showed a clear treatment-related benefit on a white-matter measure versus placebo, supporting biological target engagement.
  • The signal strengthened in patients selected for elevated inflammation biomarkers, reinforcing the company’s precision-medicine enrollment strategy for its registrational program.
  • The full imaging dataset is scheduled for presentation at AAIC 2026 on July 12-15 in London.
  • The update underpins plans for a seamless Phase 2b/3 study in inflammation-positive early Alzheimer’s, supported by FDA Fast Track status.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020800PRIMZONEFULLFEED9729915) on June 02, 2026, and is solely responsible for the information contained therein.